ST7/LRP12 Antibody [Alexa Fluor™ Plus 680]

• Reactivity: Hu
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor Plus 680

ST7/LRP12 Antibody [Alexa Fluor™ Plus 680] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human ST7/LRP12
• Specificity: Detects human ST7/LRP12 in direct ELISAs and Western blots. In direct ELISAs, 100% cross-reactivity with recombinant mouse ST7/LRP12 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for ST7/LRP12 Antibody [Alexa Fluor™ Plus 680]

• DKFZp762O2113
• FAM4A1
• LRP12
• Protein FAM4A1
• Protein HELG
• RAY1
• SEN4
• ST7
• subfamily A, member 1
• suppression of tumorigenicity 7 (breast)
• suppression of tumorigenicity 7
• suppressor of tumorigenicity 7 protein
• TSG7

Background

ST7 (Suppressor of Tumorigenicity 7), also known as RAY1, TSG7 and FAM4A1, is a type I transmembrane protein belonging to the LDLR superfamily and is designated LRP12 (1-3). The human ST7 cDNA encodes 859 amino acids (aa) including a 32 aa signal sequence, a 460 aa extracellular domain (ECD) containing two CUB domains and five LDLR class A domains, a 21 aa transmembrane domain, and a 346 aa cytoplasmic domain containing motifs implicated in endocytosis and signal transduction (1, 2). Human ST7 shares 95% aa sequence homology with mouse and rat, 96% with canine, and 98% with bovine, equine and porcine ST7 within the ECD. Genomic sequencing indicates the possibility of up to 18 splicing isoforms, but expression of these has not been well-studied (3). ST7 is widely expressed in normal tissues, especially fibroblasts (1, 4). Highest mRNA levels were detected in heart and skeletal muscle (1). ST7 was originally proposed to be a tumor suppressor protein, but it is not consistently down‑regulated in a variety of cancers, either by mutation or loss of heterozygosity (1, 4-7). In certain cancers, expression may even be up‑regulated (8). Expression may be associated with down‑regulated expression of extracellular matrix molecules that are involved in remodeling, such as SPARC, IGFBP5 and several matrix metalloproteinases, and modulation of in vivo tumorigenicity (4, 5).

1. Qing, J. et al. (1999) Oncogene 18:335.
2. Battle, M.A. et al. (2003) Biochemistry 42:7270.
3. Vincent, J.B. et al. (2002) Genomics 80:283.
4. Zenclusen, J.C. et al. (2001) Nat. Genet. 27:392.
5. Hooi, C.F. et al. (2006) Oncogene 25:3924.
6. Sivasundaram, K. et al. (2003) Oncol. Rep. 10:1737.
7. Dong, S.M. and D. Sidransky (2002) Clin. Cancer Res. 8:2939.
8. Garnis, C. et al. (2004) Oncogene 23:2582.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.